Leuven researchers have deployed synthetic amyloids to trigger protein misfolding as a strategy to combat the influenza A and Zika virus.
Amyloids are particular protein assemblies with properties similar to silk, that serve numerous functions. They also form upon protein misfolding resulting in protein inactivation.
Frederic Rousseau and Joost Schymkowitz (VIB-KU Leuven) used these properties to invent synthetic amyloid peptides that can be tailored to switch-off the function of desired target proteins. These peptides, termed Pept-ins, already proved to be a valuable approach to tackle bacterial pathogens or slow down tumor growth. Now, Schymkowitz and Rousseau’s team wanted to explore whether pept-ins could also be used to inactivate viral proteins and thereby interfere with viral replication.
The researchers designed two Pept-ins encoding virus-specific amyloid sequences identified in influenza A and Zika virus proteins, respectively. In collaboration with Xavier Saelens (VIB-UGent) and Johan Neyts (KU Leuven), they tested the antiviral properties of these molecules.
“We found that each amyloid interferes with the replication of the corresponding virus,” explains Emiel Michiels, PhD student in the lab of Schymkowitz and Rousseau. The effects turned out to be specific, adds Michiels: “For influenza A we show that our synthetic amyloid accumulates at the site of infection and interferes with viral replication in mice. The amyloid binds to the viral target protein, forcing the protein into a non-functional conformation. Influenza B is not affected by this Pept-in, highlighting the sequence specificity of this interaction.”
The new antiviral applications broaden the therapeutic potential of the Pept-in technology platform, which is explored by Aelin Therapeutics—a spin-off company based on Schymkowitz and Rousseau’s research. The researchers hope to investigate whether the same approach also work to target other types of viruses.
Reverse engineering synthetic antiviral amyloids, Michiels et al. 2020, Nature Communications
Questions from patients
A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: firstname.lastname@example.org. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.